Benefit of Ruxolitinib Treatment in Polycythemia Vera by Dr. Verstovsek

PAN Foundation provides patient assistance program for medications for MPN patients
MPN Cancer Connection partners with PAN Foundation on Medication Assistance Programs for MPN Patients
December 21, 2018

Benefit of Ruxolitinib Treatment in Polycythemia Vera by Dr. Verstovsek

Dr. Verstovsek on Benefit of Ruxolitinib in Polycythemia Vera

Dr. Verstovsek on Benefit of Ruxolitinib Treatment in PV

Srdan Verstovsek, MD, PhD, director of the Hanns A. Pielenz Clinical Research Center for Myeloproliferative Neoplasms at The University of Texas MD Anderson Cancer Center, discusses the benefit of ruxolitinib (Jakafi) in the treatment of patients with polycythemia vera (PV).

Not only has the JAK inhibitor ruxolitinib become the standard of care for the second-line treatment of these patients, Verstovsek says, the benefit of the drug is greater than what has been seen in clinical trials.  Importantly, ruxolitinib is effective in improving iron levels, and iron deficiency is the hallmark of PV.  Iron essentially serves as food for the rapidly growing red blood cells, and iron deficiency is typically symptomatic, he adds.

Ruxolitinib has maintained durable responses in patients beyond 4 years, which is already much longer than what the drug has demonstrated in patients with myelofibrosis.

CLICK HERE for More


 

Comments are closed.

Do NOT follow this link or you will be banned from the site!
Malcare WordPress Security